1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62C84E14C70F033E08525773D0020157E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/government-affairs-trends-effective-reporting-structures?opendocument
18
19opendocument
203.80.224.52
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Quality, Compliance and Regulatory Government Affairs and Public Policy

Government Affairs & Public Policy Excellence: Optimizing Group Structure

ID: 5092


Features:

15 Info Graphics

12 Data Graphics

50 Metrics

6 Narratives


Pages/Slides: 37


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Government Affairs & Public Policy Excellence: Optimizing Group Structure"

STUDY OVERVIEW

Reimbursement, regulatory and political issues weigh heavily on an organization's success in the marketplace, and thus the Government Affairs and Public Policy functions play a vital and growing role in overall organizational success in the biopharma sector. With the pharmaceutical industry placing a heavy reliance on their Government Affairs and Public Policy functions, it is essential for these groups to have structures that promote effectiveness and efficiency. That structural effectiveness needs to extend to how they are aligned with internal customers as well as external stakeholders. This study identifies the key drivers of Government Affairs organizational structure, internal customer alignment and reporting lines. Managers and executives in Government Affairs can use this research to compare their group's structure with leading organizations.

KEY TOPICS

  • Government Affairs & Policy group structures: Key trends & drivers of sub-group evolution
  • Government Affairs & Policy leadership models: Effective reporting structures
  • Government Affairs & Policy group models and structures

SAMPLE KEY METRICS
  • Functional factors that describe how your Government Affairs group is organized
  • Geographic factors that describe how your Government Affairs group is organized
  • Approaches Government Affairs uses to align with internal customers
  • Effectiveness of different staffing approaches for serving internal customers
  • Approaches to integrating Federal, State and International GA structures
  • Level of person leading your Government Affairs group
  • Group that Government Affairs reports to
  • Specialty areas within GA with sub-groups
  • Is policy physically located in same place as Government Affairs
  • Level of person leading Public Policy
  • Policy's relation to Legal
  • Where does PAC function reside

SAMPLE KEY FINDING
  • Differentiated Services Are the Norm for Government Affairs: Almost three-quarters of participants said they vary the level of services – staffing, time, and responsiveness – across internal customers. The practice reflects the significant impact that Government Affairs can have on important business issues such as reimbursement and regulatory. It further underscores how small expert staffs provide services to diverse stakeholders while reflecting differences in stakeholder issues and impact.

METHODOLOGY

Participants ranging from middle level management to senior executives at 15 leading bio-pharmaceutical, healthcare and medical device companies participated in the study. Field interviews and study analysis produced many observations and benchmark findings to reflect opportunities across the Public Policy and Government Affairs functions.


Industries Profiled:
Pharmaceutical; Health Care; Biotech; Chemical; Medical Device


Companies Profiled:
Boehringer Ingelheim; Novo Nordisk; Abbott Laboratories; Genentech; AstraZeneca; Roche; UCB Pharma; GlaxoSmithKline; Solvay Pharmaceuticals; Stiefel; Pfizer; Lilly; Baxter International; Cephalon; Inc.; DRI; Biomarin


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.